More than 280 teens & young men suffer heart inflammation after Pfizer or Moderna Covid jab – sparking CDC ’emergency’
THE CDC has planned an emergency meeting after 283 teenage boys and young men suffered heart inflammation after the Pfizer or Moderna Covid jab.
The agency will gather on June 18 to discuss plausible causes of the inflammation that has been found in young people.
The CDC and other health regulators have been investigating heart inflammation cases after Israel’s Health Ministry reported that it had found a likely link to the condition in young men who received the Pfizer vaccine.
The agency said it is still assessing the risk from the condition and has not yet concluded that there was a causal relationship between the vaccines and cases of myocarditis or pericarditis.
More than half of the cases reported to the US Vaccine Adverse Event Reporting System (VAERS) after people had received their second dose of either the Pfizer or Moderna vaccines were in people between the ages of 12 and 24, the CDC said.
Those age groups accounted for less than nine percent of doses administered.
“We clearly have an imbalance there,” Dr. Tom Shimabukuro, deputy director of the CDC’s Immunization Safety Office, said on Thursday.
The overwhelming majority of the cases have occurred within a week of vaccination, Shimabukuro said.
There were 283 observed cases of heart inflammation after the second vaccine dose in those aged 16 to 24 in the VAERS data.
That compares with expectations of 10-to-102 cases for that age range based on US population background incidence rates, the CDC said.
Shimabukuro said there was a predominance of males in younger age groups among the reported heart inflammation cases.
The median age of patients who experienced the inflammation after a second vaccine dose was 24, according to the VAERS data. Just under 80 percent of the cases were in men.
Shimabukuro also said the Vaccine Safety Datalink – another safety monitoring system – showed an increased incidence of heart inflammation in 16 to 39-year-olds after their second shot when compared to the rate observed after the first dose.
